US Equities Analysis

COR — Cencora

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 1.72%
Profit Margins 0.78%
Return on Equity 107.13%
Return on Assets 3.49%
Free Float 0.18B
Dividend Yield 0.84%
Short Int % Utilisation 3.22%

2.2 Growth

Metric Value
Revenue Growth 3.8%
Free Cash Flow -0.32B
EBITDA 12.79 (Ratio)
Enterprise Value 67.82B
EV/Revenue 0.21
EV/EBITDA 12.79

Revenue growth of 3.8% suggests mature or challenged top-line momentum.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.)* 13.62%
Risk / Std Dev (Ann.)* 31.69%
1-Year Price Return* 7.78%

Latest Market Data (as of 2026-08-14, US Eastern time):

Metric Value
Last Price $313.82
52-Week Range $244.82 – $377.54
Observation Count 251 trading days

The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating input Value
Revenue $321.33B
Prior annual revenue $293.96B
EBIT $2.68B
Tax rate 30.58%
NOPAT = EBIT × (1 − tax rate) $1.86B
Forecast start-growth basis 9.31%
Forecast policy latest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building block Value
NOPAT $1.86B
Add: depreciation & amortisation $1.07B
Less: capital expenditure -$667.98M
Less/(add): working-capital cash-flow movement $35.42M
Current unlevered FCFF $2.30B

Explicit FCFF forecast

Forecast year Revenue growth NOPAT D&A Capex Change in NWC FCFF Present value
1 9.31% $2.03B $1.17B -$730.19M $38.72M $2.51B $2.42B
2 7.61% $2.19B $1.26B -$903.50M $41.67M $2.58B $2.32B
3 5.91% $2.32B $1.33B -$1.08B $44.13M $2.61B $2.18B
4 4.20% $2.41B $1.39B -$1.26B $45.99M $2.59B $2.01B
5 2.50% $2.47B $1.42B -$1.42B $47.13M $2.52B $1.82B

Step 3 — Determine the Discount Rate (WACC)

WACC input Value
Risk-free rate 4.71%
Equity risk premium assumption 5.50%
Beta 0.57
Cost of equity 7.86%
Pre-tax cost of debt 6.97%
WACC 7.53%
WACC validation within standard range

Step 4 — Estimate Terminal Value

Terminal-value input Value
Perpetuity growth rate 2.50%
Terminal value $51.42B
Implied terminal EV / EBITDA 10.31x
Terminal value as % of enterprise value 76.91%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value component Value
Present value of explicit FCFF $10.74B
Present value of terminal value $35.77B
Indicated enterprise value $46.51B
Discounting convention mid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridge Value
Indicated enterprise value $46.51B
Less: gross interest-bearing debt $7.66B
Add: cash and equivalents $4.36B
Add: affiliate investments $0.00
Less: minority interests $239.07M
Indicated common equity value $42.97B

Step 7 — Calculate Indicative Value Per Share

Per-share output Value
Shares used 195,214,000.00
Share-count basis reported diluted weighted-average shares
Current market price $319.59
DCF indicative value per share $220.10
Indicative value vs. market price -31.13%

Model Integrity Checks

Check Result
Perpetuity growth is below the risk-free rate pass
Perpetuity growth is below WACC pass
WACC is within the configured operating-company range pass
Terminal-year FCFF is positive pass
Terminal capex converges to D&A pass
Terminal-value concentration within review band
Implied price differs from spot by more than 30% review required

2.6 Investor-Style Research Screen

Educational screen Result
Buffett-inspired cash-quality checks 4/4 evidenced checks
Lynch-inspired balance-and-growth checks 4/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:27:59.871626 UTC; latest reported fiscal period: 2025-09-30 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

us-equity stock equity cor health-care health-care-distributors nasdaq